Sarah brings over two decades of experience in driving innovation from early research to clinical development across multiple therapeutic areas. She was previously Chief Scientific Officer at CHARM Therapeutics, spearheading R&D strategy, portfolio development, and integration of AI to accelerate oncology pipeline progression.
Prior to CHARM, Sarah held senior scientific roles at MSD, Vertex, Biogen, and Pfizer, leading multidisciplinary teams and overseeing preclinical research in diseases of ageing, neuroscience, pain, and genitourinary disorders. She has a strong track record of delivering therapeutic programs to the clinic, and has contributed to numerous patents and high-impact publications.
Sarah received her PhD in organic chemistry at the University of Nottingham and undertook her postdoctoral studies at Stanford University as a visiting Fulbright Scholar. With a collaborative and entrepreneurial mindset, she is passionate about translating scientific breakthroughs into transformative healthcare solutions.
